Similar Items: Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan
- Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis
- Cost–Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan
- Successful Treatment of IL‐23 Inhibitor–Refractory Nail Psoriasis With Deucravacitinib: A Case Report
- Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review
- New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review
- Personalized Medicine in Psoriasis – A Long Road Ahead?